Latest Us Market Expansion News

Micro-X has secured its first supply agreement with a leading US healthcare provider for its Rover Plus mobile radiology system, opening access to over 700 facilities nationwide.

dorsaVi has acquired exclusive global rights to advanced RRAM technology, promising major performance gains in its biomedical sensors, while securing key contracts and raising $2.44 million to fuel US market growth.

AML3D has appointed Arc Additive as its UK and European distribution partner, marking a strategic push into key manufacturing and defence markets across Europe. This move follows a successful capital raise and a contract with BAE Systems UK, underpinning AML3D’s growth ambitions.

Singular Health has landed a pivotal $2 million US pilot contract with Provider Network Solutions and completed an $8 million capital raise, advancing its medical imaging platform’s regulatory and product development milestones.

Treasury Wine Estates has named Breakthru Beverage Group as its exclusive distributor in California, stepping in after Republic National Distributing Company exits the state. The move marks a significant shift in TWE’s US distribution strategy with financial impacts yet to be fully revealed.

Pure Resources advances its Reedy Creek project by exploring graphite potential and forging US partnerships to tap into thermal management and rare earth element technologies.

Echo IQ has secured a pivotal reseller agreement with US-based SARC MedIQ, unlocking access to over 300 healthcare facilities and accelerating adoption of its AI-driven EchoSolv AS technology across the American cardiology landscape.

The Calmer Co. International Limited has reported a striking 86% revenue jump to over AU$8 million in FY25, propelled by diversified sales channels and a strategic US expansion highlighted by new flavoured kava shots launched exclusively on Amazon USA.

Orthocell Limited has posted a record quarterly revenue of A$2.73 million, driven by strong Australian sales of its nerve repair product Remplir™, with US market expansion poised to accelerate in FY26.

Orthocell has marked a pivotal milestone with the first US surgical use of its Remplir™ nerve repair device following FDA clearance, setting the stage for commercial expansion in a $1.6 billion market.

Xero has completed a significant A$1.85 billion institutional placement to fund its acquisition of Melio, aiming to enhance its accounting and payments platform in the US market. A complementary A$200 million Share Purchase Plan will offer retail investors a chance to participate.

Xero Limited has announced a binding agreement to acquire Melio Limited for US$2.5 billion, backed by a fully underwritten A$1.85 billion equity raise. This strategic move aims to accelerate Xero’s US growth and more than double its FY25 revenue by FY28.